Breathe Right(R) Nasal Strip Patent Unchanged Following Patent Office Re-examination.MINNEAPOLIS -- CNS See Continuous net settlement. CNS See continuous net settlement (CNS). , Inc. (Nasdaq:CNXS), the Breathe Right Breathe Right™ Sports medicine A proprietary Band-Aid™-like nasal strip worn on the nasal bridge, said to improve breathing by opening the nasal passages Indications Temporary relief of breathing difficulties due to deviated nasal Company, today announced that the U.S. Patent and Trademark Office has completed its re-examination and published the certificate for U.S. Patent Number 6,318,362. The re-examination certificate was granted without any changes to the original claims of the '362 patent, one of several key patents covering the design of the Breathe Right(R) nasal strip. The re-examination by the U.S. Patent Office was performed at the request of the defendant in a patent infringement patent infringement n. the manufacture and/or use of an invention or improvement for which someone else owns a patent issued by the government, without obtaining permission of the owner of the patent by contract, license or waiver. suit initiated by CNS. "We are pleased by the timely completion of the re-examination of the '362 patent," said Marti Morfitt, president and chief executive officer of CNS, Inc. "Breathe Right nasal strips are an effective and very successful product line which attracts companies that attempt to infringe upon our patented technologies. We will continue to aggressively enforce and defend our patent rights, and will use the reissued '362 patent to prosecute legal proceedings All actions that are authorized or sanctioned by law and instituted in a court or a tribunal for the acquisition of rights or the enforcement of remedies. against infringing companies," said Morfitt. About CNS, Inc. CNS, based in Minneapolis, designs and markets consumer health care products, including Breathe Right(R) nasal strips and FiberChoice(R) dietary fiber dietary fiber n. Coarse, indigestible plant matter, consisting primarily of polysaccharides, that when eaten stimulates intestinal peristalsis. supplements. The company focuses on products that address important consumer needs within the aging well/self-care market, including better breathing and digestive health. Its common stock is listed on the Nasdaq National Market under the ticker symbol Ticker Symbol An arrangement of characters (usually letters) representing a particular security listed on an exchange or otherwise traded publicly. When a company issues securities to the public marketplace, it selects an available ticker symbol for its securities which investors "CNXS." More information about CNS and its products is available at www.cns.com. Some of the statements contained in this news release contain forward-looking statements that are subject to certain business risks, including those risks described in the Company's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended March 31, 2006, as well as other filings with the Securities and Exchange Commission. The Company undertakes no duty or obligation to update any of the forward-looking statements after the date of this release. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion